Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma - Quiz - MDSpire

Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma

  • By

  • Meera Mohan

  • Aniko Szabo

  • Heloise Cheruvalath

  • Anna Clennon

  • Vineel Bhatlapenumarthi

  • Anannya Patwari

  • Metodi Balev

  • Divaya Bhutani

  • Asis Shrestha

  • Sharmilan Thanendrarajan

  • Binod Dhakal

  • Maurizio Zangari

  • Anup Trikannad

  • Sruthi Vellanki

  • Samer Al-Hadidi

  • Suzanne Lentzsch

  • Frits van Rhee

  • Aishee Bag

  • Anita D’Souza

  • Nishi Shah

  • Rajshekhar Chakraborty

  • Mansi R. Shah

  • Carolina Schinke

  • April 23, 2025

  • 0 min

Share

Original Source(s)

Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma

  • by Meera Mohan, Aniko Szabo, Heloise Cheruvalath, Anna Clennon, Vineel Bhatlapenumarthi, Anannya Patwari, Metodi Balev, Divaya Bhutani, Asis Shrestha, Sharmilan Thanendrarajan, Binod Dhakal, Maurizio Zangari, Anup Trikannad, Sruthi Vellanki, Samer Al-Hadidi, Suzanne Lentzsch, Frits van Rhee, Aishee Bag, Anita D’Souza, Nishi Shah, Rajshekhar Chakraborty, Mansi R. Shah, Carolina Schinke

  • April 23, 2025

Related Content

Not all plasma cells are made equal: well-hidden layers of heterogeneity

Targeting CD38 Enzymatic Function in Antibody-Driven Immunotherapy for Multiple Myeloma: Insights from Basic Research

Proteomic and Metabolomic Profiling via Mass Spectrometry in Multiple Myeloma: A Comprehensive Review of Prognostic Biomarkers and Monitoring of Minimal Residual Disease